Key result
Adding plasma SVEP1 to clinical models improves major cardiovascular events prediction in HCM.
Why the study?
It was unknown whether adding plasma SVEP1 levels to clinical predictors, including NT-proBNP, improves prognostication of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy.
Does adding plasma SVEP1 levels to clinical predictors improve the prognostication of MACE in patients with hypertrophic cardiomyopathy?
Cohort (n=610)
Yes
Does adding plasma SVEP1 levels to clinical predictors improve the prognostication of MACE in patients with hypertrophic cardiomyopathy?
Plasma SVEP1 levels serve as a novel biomarker that improves the prediction of major adverse cardiovascular events in hypertrophic cardiomyopathy beyond conventional risk models.
Answers are grounded in this paper and cite their sources.
Should not yet change HCM risk stratification; leaves open SVEP1 as a candidate biomarker for prospective validation.
BACKGROUND: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing 1) is a large extracellular matrix protein that is detectable in the plasma. However, it is unknown whether adding plasma SVEP1 levels to clinical predictors including NT-proBNP (N-terminal pro-B-type natriuretic peptide) improves the prognostication in patients with hypertrophic cardiomyopathy. METHODS: We performed a multicenter prospective cohort study of 610 patients with hypertrophic cardiomyopathy. The outcome was MACE defined as heart failure hospitalization or cardiac death. In 4 groups stratified by the median levels of SVEP1 and NT-proBNP, we compared the risk of MACE using the Cox proportional hazards model adjusting for 15 clinical predictors. We also developed a Lasso-regularized Cox proportional hazards model to predict time to first MACE by adding SVEP1 to the 15 clinical predictors with or without NT-proBNP and compared the predictive performance based on C statistics using 10-fold cross-validation. CONCLUSIONS: SVEP1 improved the predictive performance of conventional models, including known clinical parameters with or without NT-proBNP, to predict future MACE in patients with hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Osawa et al. (2025) conducted a cohort in Hypertrophic cardiomyopathy (n=610). Plasma SVEP1 levels vs. Conventional clinical risk models with or without NT-proBNP was evaluated on MACE defined as heart failure hospitalization or cardiac death (p==0.04). Adding plasma SVEP1 levels to conventional clinical models improved the prediction of future major cardiovascular events (heart failure hospitalization or cardiac death) in hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: